Novavax Reports Second Quarter 2017 Financial Results
8.8.2017 22:05 | NASDAQ OMX
GAITHERSBURG, Md., Aug. 08, 2017 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX) today announced its financial results for the second quarter and six months ended June 30, 2017.
Second Quarter and Subsequent Achievements:
- Novavax' nanoparticle flu vaccine demonstrates superior immunogenicity and protection compared to market leader in preclinical challenge studies. In head-to-head comparison studies against Fluzone® High-Dose, Novavax' nanoparticle influenza vaccine with our proprietary Matrix-M(TM) adjuvant (NanoFlu) demonstrated significantly stronger and broader immune responses against matched and unmatched influenza strains, including a series of "drifted" strains evolved over more than a decade of influenza seasons. NanoFlu was also protective in an established challenge model against both a matched and a ten-year old unmatched strain. Further details will be published in the near future in a peer-reviewed journal and presented at scientific conferences.
- Topline data from Phase 2 older adult safety and immunogenicity trial (E-205) demonstrated the benefit of adjuvanted formulations and two-dose regimens. Immunogenicity outcomes indicate both Matrix-M and aluminum phosphate adjuvants significantly increased the magnitude, duration and quality of the immune response relative to the RSV F antigen alone. All formulations and regimens were safe and well-tolerated.
- The Company announced the path forward for an adjuvanted RSV F protein recombinant nanoparticle vaccine (RSV F Vaccine) in older adults with plans to initiate a Phase 2 efficacy trial in 2018. This approach is driven by an observed 61% reduction in hospitalizations due to COPD exacerbations.
- The Prepare(TM) clinical trial for infants via maternal immunization, supported by an $89 million grant from the Bill and Melinda Gates Foundation (BMGF), accelerated into the third global season of enrollment. Prepare's global footprint has grown from 16 sites in five countries in its first season of enrollment to 80 sites in 11 countries.
- Data from the second of two Phase 2 trials of its RSV F Vaccine candidate confirmed an overall reduction of infection of >50% in women of childbearing age, published in the journal Vaccine.
Anticipated 2017 Event:
- Initiation of a Phase 1/2 clinical trial of the Company's NanoFlu vaccine candidate in a head-to-head comparison to Fluzone High-Dose. Data from this trial should be available in the fourth quarter of 2017.
"Novavax has demonstrated considerable progress in our RSV F Vaccine program, highlighted by the continued strong execution of the Prepare trial, and the data from our recent trial in older adults, which confirmed the ability of the vaccine to generate robust immune responses and provided us with a development path forward," said Stanley C. Erck, President and CEO. "We are also excited by the recent preclinical results of our nanoparticle influenza vaccine and look forward to Phase 1/2 clinical data in the fourth quarter of this year."
Financial Results for the Three and Six Months Ended June 30, 2017
Novavax reported a net loss of $44.5 million, or $0.16 per share, for the second quarter of 2017, compared to a net loss of $79.4 million, or $0.29 per share, for the second quarter of 2016. For the six months ended June 30, 2017, the net loss was $88.3 million, or $0.32 per share, compared to a net loss of $156.6 million, or $0.58 per share, for the same period in 2016.
Novavax revenue in the second quarter of 2017 increased 169% to $6.7 million, compared to $2.5 million for the same period in 2016, primarily due to increased revenue recorded under the BMGF grant relating to our ongoing Prepare clinical trial.
Research and development expenses decreased 40% to $39.3 million in the second quarter of 2017, compared to $64.9 million for the same period in 2016. The decrease was primarily due to reduced costs associated with the clinical trials and development activities of our RSV F Vaccine and lower employee-related costs.
General and administrative expenses decreased 37% to $8.9 million in the second quarter of 2017, compared to $14.1 million for the same period in 2016. The decrease was primarily due to lower professional fees for pre-commercialization activities and lower employee-related costs.
Interest income (expense), net for the second quarter of 2017 was ($3.0) million, compared to ($2.8) million for the same period in 2016.
As of June 30, 2017, the company had $187.3 million in cash and cash equivalents and marketable securities compared to $235.5 million as of December 31, 2016. Net cash used in operating activities for the first six months of 2017 was $69.4 million, compared to $131.9 million for same period in 2016. The decrease in cash usage was primarily due to decreased costs relating to our RSV F Vaccine and lower overall employee-related costs.
Novavax management will host its quarterly conference call today at 4:30 p.m. ET. The dial-in number for the conference call is (877) 212-6076 (Domestic) or (707) 287-9331 (International), passcode 15614203. A replay of the conference call will be available starting at 7:30 p.m. ET on August 8, 2017 until 7:30 pm ET on August 15, 2017. To access the replay by telephone, dial (855) 859-2056 (Domestic) or (404) 537-3406 (International) and use passcode 15614203.
A webcast of the conference call can also be accessed via a link on the home page of the Novavax website (novavax.com) or through the "Investor Info"/"Events" tab on the Novavax website. A replay of the webcast will be available through the "Investor Info"/"Events" tab on the Novavax website until November 8, 2017.
Novavax, Inc. (Nasdaq:NVAX) is a clinical-stage biotechnology company committed to delivering novel products to prevent a broad range of infectious diseases. Our recombinant nanoparticles and Matrix-M(TM) adjuvant technology are the foundation for groundbreaking innovation that improves global health through safe and effective vaccines. Additional information about Novavax is available on the Company's website, novavax.com.
Statements herein relating to the future of Novavax and the ongoing development of its vaccine and adjuvant products are forward-looking statements. Novavax cautions that these forward looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include those identified under the heading "Risk Factors" in the Novavax Annual Report on Form 10-K for the year ended December 31, 2016 and the Quarterly Report on Form 10-Q for the period ended June 30, 2017, both as filed with the Securities and Exchange Commission (SEC). We caution investors not to place considerable reliance on the forward-looking statements contained in this press release. You are encouraged to read our filings with the SEC, available at sec.gov, for a discussion of these and other risks and uncertainties. The forward-looking statements in this press release speak only as of the date of this document, and we undertake no obligation to update or revise any of the statements. Our business is subject to substantial risks and uncertainties, including those referenced above. Investors, potential investors, and others should give careful consideration to these risks and uncertainties.
|CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS|
|(in thousands, except per share information)|
|Three Months Ended||Six Months Ended|
|June 30,||June 30,|
|Research and development||39,263||64,904||76,916||133,856|
|General and administrative||8,940||14,099||17,793||24,627|
|Loss from operations||(41,471||)||(76,498||)||(82,297||)||(151,760||)|
|Interest income (expense), net||(2,993||)||(2,842||)||(6,032||)||(4,799||)|
|Other income (expense)||(1||)||(11||)||10||(44||)|
|Basic and diluted net loss per share||$||(0.16||)||$||(0.29||)||$||(0.32||)||$||(0.58||)|
|Basic and diluted weighted average|
|number of common shares outstanding||283,444||270,760||278,836||270,469|
SELECTED CONSOLIDATED BALANCE SHEET DATA
|Cash and cash equivalents||$||75,793||$||144,353|
|Total current assets||236,683||287,830|
|Total notes payable and capital lease obligation||317,051||316,376|
|Total stockholders' deficit||(59,062||)||(5,546||)|
Andrea N. Flynn, Ph.D.
Director, Investor Relations
Russo Partners, LLC
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Novavax, Inc. via Globenewswire
Följ NASDAQ OMX
Skriv in din e-postadress så får du ett mejl när vi har något nytt att berätta.
Senaste pressmeddelandena från NASDAQ OMX
Constellation Brands to Present at Barclays Global Consumer Staples Conference, September 6, 201722.8.2017 15:04 | Pressmeddelande
VICTOR, N.Y., Aug. 22, 2017 (GLOBE NEWSWIRE) -- Constellation Brands, Inc. (NYSE:STZ) (NYSE:STZ.B), a leading beverage alcohol company, announced today that David Klein, chief financial officer and Bill Newlands, chief operating officer, will present at the Barclays Global Consumer Staples Conference on Wednesday, September 6, 2017, at the Intercontinental Hotel in Boston, MA. The presentation is scheduled to begin at 11:15 a.m. EDT and is expected to cover the company's strategic business activities, financial and operational performance, and outlook for the future. A live audio webcast of the presentation can be accessed on the company's website at www.cbrands.com by following the instructions in the "Investors" section. Following the presentation, the webcast will be available on the company's website for replay through the close of business on Friday, October 27, 2017. Financial and statistical information discussed in the presentation and a reconciliat
Patton Among Top Ten 2017 UC Solutions Providers22.8.2017 14:00 | Pressmeddelande
Patton offers a unique set of competencies and capabilities that help companies bring their UC dreams into reality GAITHERSBURG, Md., Aug. 22, 2017 (GLOBE NEWSWIRE) -- Patton Electronics-US manufacturer of UC, cloud, and IoT enabling solutions for carrier, enterprise and industrial networks-has been named among the top ten unified communications (UC) solutions providers according to InsightsSuccessmagazine. Patton is doing some unusual things that no other network equipment manufacturer does to enable UC implementations. Patton offers a unique set of competencies and capabilities that help companies bring their UC dreams into reality. Two examples... SmartNode enterprise session border controllers (eSBC) address a broad range of networking functions including IP security, legacy telephony integration (analog and ISDN), network demarcation, and much more-all in a single customer
Manuport Logistics Uses Descartes for SOLAS Compliance22.8.2017 12:45 | Pressmeddelande
LIER, Belgium, Aug. 22, 2017 (GLOBE NEWSWIRE) -- Descartes Systems Group (Nasdaq:DSGX) (TSX:DSG), the global leader in uniting logistics-intensive businesses in commerce, announced that Manuport Logistics in Belgium is using the Descartes Verified Gross Mass(TM) (Descartes VGM(TM)) solution to help its customers comply with the International Convention for the Safety of Life at Sea (SOLAS) regulations for container weight requirements. "The long-standing relationship Manuport has with Descartes played an important role in our selection of the Descartes VGM solution; however, it was the rapid implementation capabilities that really differentiated Descartes," said Luc Geerts, Strategic Accounts Manager at Manuport Logistics. "In addition, Descartes has an impressive track record in networked communication and the Descartes VGM solution uses a similar Descartes standard message format as we do for managing shipments. In the maritime industry where messaging standards
Immunicum AB (publ) Announces Upcoming Presentations at Conferences in August and September22.8.2017 08:00 | Pressmeddelande
Press Release 22 August 2017 Immunicum AB (publ) Announces Upcoming Presentations at Conferences in August and September Immunicum AB (publ; First North Premier: IMMU.ST) a biopharmaceutical company advancing a novel, immune-priming cancer treatment against a variety of solid tumors, today announced that Immunicum leadership will present the Company at several upcoming investor and partnering conferences in August and September. Swedish-American Life Science Summit 2017 Date: August 23 - 25, 2017 Presentation Time: August 25, 12:00 pm Central European Time Venue: Nasdaq Stockholm, Tullvaktsvägen 15, Stockholm, Sweden Pareto Securities' 8th Annual Healthcare Conference Date: September 7, 2017 Presentation Time: 12:15 pm Central European Time Venue: Conference 7A Strandvägen 7A Stockholm, Sweden 24th Annual NewsMakers in th
Kommande presentationer och investerarmöten i augusti och september22.8.2017 08:00 | Pressmeddelande
Pressmeddelande 22 augusti 2017 Kommande presentationer och investerarmöten i augusti och september Immunicum AB (publ), First North Premier: (IMMU.ST), ett bioteknikbolag som utvecklar ny typ av immunaktiverande cancerbehandling mot ett flertal olika solida tumörformer, meddelar idag att bolagets ledning kommer att presentera bolaget vid ett flertal kommande konferenser och investerarmöten under augusti och September. Swedish-American Life Science Summit 2017 (SALSS) Datum: 23-25 augusti, 2017 TIdpunkt för Immunicums presentation: 25 augusti, kl 12:00 Plats: Nasdaq Stockholm, Tullvaktsvägen 15, Stockholm Pareto Securities' 8th Annual Healthcare Conference Datum: 7 september, 2017 Tidpunkt för Immunicums presentation: kl 12:15 Plats: Conference 7A Strandvägen 7A Stockholm 24th Annual NewsMakers in the Biotech Industry
ZIM Adds MatchBack Systems Analytics Services in Italy21.8.2017 22:00 | Pressmeddelande
Innovative approach to gain efficiencies through fewer empty container moves adds significant value for ZIM's customers GREEN BAY, Wis. and ROTTERDAM, The Netherlands, Aug. 21, 2017 (GLOBE NEWSWIRE) -- MatchBack Systems, Inc. ( www.matchbacksystems.com ), the leading software as a service (SaaS) solution to plan, optimize and automate matchbacks, announced that ZIM Integrated Shipping Ltd. joined the company's customer base on May 1, 2017 to optimize their inland operation in Italy. The account will be serviced through the European office in Rotterdam and corporate headquarters in North America. The system will be deployed for a 2 months pilot after which the parties will evaluate the scope for a broader cooperation. A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/1cb9a632-22a4-4ff5-a3d5-d8b3964e5113 Gil Lehmann, Head of Global Land Tra
I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.Besök vårt pressrum